Search

Your search keyword '"Giannini E. G."' showing total 22 results
Start Over Author "Giannini E. G." Search Limiters Peer Reviewed
22 results on '"Giannini E. G."'

1. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

Author

Petta, S., Cabibbo, G., Barbara, M., Attardo, S., Bucci, L., Farinati, F., Giannini, E. G., Tovoli, F., Ciccarese, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Virdone, R., Marra, F., Felder, M., Morisco, F., Benvegnù, L., Gasbarrini, A., Svegliati‐Baroni, G., Foschi, F. G., Olivani, A., Masotto, A., Nardone, G., Colecchia, A., Persico, M., Boccaccio, V., Craxì, A., Bruno, S., Trevisani, F., Cammà, C., Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Piscaglia, Fabio, Gramenzi, Annagiulia, Granito, Alessandro, Magalotti, Donatella, Serra, Carla, Negrini, Giulia, Napoli, L., Napoli, Lucia, Salvatore, Veronica, Benevento, Francesca, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Moscatelli, Alessandro, Pellegatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Poggio, Paolo Del, Olmi, Stefano, de Matthaeis, Nicoletta, Balsamo, Claudia, Vavassori, Elena, Roselli, Paola, DellʼIsola, Serena, Ialungo, Anna Maria, Rastrelli, Elena, Rini, Francesca, Costantino, Andrea, Affronti, Andrea, Affronti, Marco, Mascari, Marta, Mega, Andrea, Pompili, Maurizio, Rinninella, Emanuele, Mismas, Valeria, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Biasini, Elisabetta, Missale, Gabriele, Guarino, Maria, Ortolani, Alessio, Chiaramonte, Maria, Marchetti, Fabiana, Valerio, Matteo, Aburas, Sami, Inghilesi, Andrea L., Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Coccoli, Piero, and Zamparelli, Marco Sanduzzi

Published
2017
Full Text
View/download PDF

3. Years of life that could be saved from prevention of hepatocellular carcinoma

Author

Cucchetti, A., Trevisani, F., Bucci, L., Ravaioli, M., Farinati, F., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Maida, M., Felder, M., Morisco, F., Gasbarrini, A., Gemini, S., Foschi, F. G., Missale, G., Masotto, A., Affronti, A., Bernardi, M., Pinna, A. D., Bolondi, Luigi, Biselli, Maurizio, Caraceni, Paolo, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Pecorelli, Anna, Serra, Carla, Venerandi, Laura, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Poggio, Paolo Del, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Bosco, Giulia, Roselli, Paola, DellʼIsola, Serena, Lalungo, Anna Maria, Rastrelli, Elena, Moscatelli, Alessandro, Pellegatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Barcellona, Maria Rosa, Virdone, Roberto, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Guarino, Maria, Baroni, Gianluca Svegliati, Schiadà, Laura, Chiaramonte, Maria, Marchetti, Fabiana, and Valerio, Matteo

Published
2016
Full Text
View/download PDF

4. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome

Author

Bucci, L., Garuti, F., Camelli, V., Lenzi, B., Farinati, F., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Maida, M., Felder, M., Morisco, F., Gasbarrini, A., Gemini, S., Foschi, F. G., Missale, G., Masotto, A., Affronti, A., Bernardi, M., Trevisani, F., Bolondi, Luigi, Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Pecorelli, Anna, Serra, Carla, Venerandi, Laura, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Poggio, Paolo Del, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Capelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Roselli, Paola, Isola, Serena, Ialungo, Anna Maria, Rastrelli, Elena, Moscatelli, Alessandro, Pelagatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Barcellona, Maria Rosa, Cammà, Calogero, Cabibbo, Giuseppe, Costantino, Andrea, Virdone, Roberto, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Biasini, Elisabetta, Porro, Emanuela, Guarino, Maria, Baroni, Gianluca Svegliati, Schiadà, Laura, Chiaramonte, Maria, Marchetti, Fabiana, and Valerio, Matteo

Published
2016
Full Text
View/download PDF

6. Risk Stratification for BD-IPMN Malignant Transformation. The role of operative dimensional grouping in the cost-effectiveness optimization of surveillance guidelines. The PACMANS Study.

Author

Kayali, S., Marabotto, E., Dibitetto, S., Gaiani, F., Busatto, A., Caprioli, S., Luzzi, A. P., Savarino, E., Laghi, L., De Angelis, C., and Giannini, E. G.

Subjects
COST effectiveness, DISEASE risk factors
Abstract

This article discusses the management and surveillance guidelines for Branch Duct Intraductal Papillary Mucinous Neoplasms (BD-IPMN), a type of pancreatic lesion. The study aimed to determine the rates of malignant degeneration of these lesions and identify associated risk factors in order to propose a more cost-effective surveillance strategy. The study found that IPMN developed malignant degeneration in 3.3% of cases, with risk factors including the presence of High-Risk Stigmata (HRS), Worrisome Features (WF), and cyst size. Based on these findings, the study proposed a new surveillance strategy that maintained diagnostic accuracy while reducing costs. [Extracted from the article]

Published
2024
Full Text
View/download PDF

17. Real life adherence to international guidelines in BD-IPMN management. Clinical and costs impact of divergent strategies in BD-IPMN care. The PACMANS Study.

Author

Kayali, S., Marabotto, E., Dibitetto, S., Fantasia, S., Busatto, A., Caprioli, S., Luzzi, A. P., Savarino, E., Laghi, L., De Angelis, C., and Giannini, E. G.

Subjects
COST
Abstract

This article, published in the journal Endoscopy, examines the adherence to international guidelines in the management of Branch Duct Intraductal Papillary Mucinous Neoplasms (BD-IPMN). The study collected data from four tertiary centers in Northern Italy from 2017 to 2023 and analyzed factors influencing non-compliance with the guidelines. The results showed that 54% of patients received recommendations that deviated from the guidelines, with a majority of these deviations being in an aggressive direction. While divergent strategies did not lead to different rates of IPMN-related mortality, they did result in increased surveillance costs compared to following the recommended guidelines. [Extracted from the article]

Published
2024
Full Text
View/download PDF

18. A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis.

Author

Biselli, M, Conti, F, Gramenzi, A, Frigerio, M, Cucchetti, A, Fatti, G, D'Angelo, M, Dall'Agata, M, Giannini, E G, Farinati, F, Ciccarese, F, Andreone, P, Bernardi, M, and Trevisani, F

Abstract

Background: Surveillance for hepatocellular carcinoma (HCC) is recommended in patients with cirrhosis. As α-fetoprotein (AFP) is considered a poor surveillance test, we tested the performance of its changes over time.Methods: Eighty patients were diagnosed with HCC (cases) during semiannual surveillance with ultrasonography and AFP measurement were recruited and matched for age, gender, etiology and Child-Pugh class with 160 contemporary cancer-free controls undergoing the same surveillance training group (TG). As a validation group (VG) we considered 36 subsequent patients diagnosed with HCC, matched 1 : 3 with contemporary cancer-free controls. α-Fetoprotein values at the time of HCC diagnosis (T0) and its changes over the 12 (Δ12) and 6 months (Δ6) before cancer detection were considered.Results: In both TG and VG, >80% of HCCs were found at an early stage. In TG, AFP significantly increased over time only in cases. T0 AFP and a positive Δ6 were independently associated with HCC diagnosis (odds ratio: 1.031 and 2.402, respectively). The area under the curve of T0 AFP was 0.76 and its best cutoff (BC) was 10 ng ml(-1) (sensitivity 66.3%, specificity 80.6%). The combination of AFP >10 ng ml(-1) or a positive Δ6 composite α-fetoprotein index (CAI) increased the sensitivity to 80% with a negative predictive value (NPV) of 86.2%. Negative predictive value rose to 99%, considering a cancer prevalence of 3%. In the VG, the AFP-BC was again 10 ng ml(-1) (sensitivity 66.7%, specificity 88.9%), and CAI sensitivity was 80.6% with a NPV value of 90.5%.Conclusions: CAI achieves adequate sensitivity and NPV as a surveillance test for the early detection of HCC in cirrhosis. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

19. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options.

Author

GIANNINI, E. G.

Subjects
*THROMBOCYTOPENIA, *DRUG therapy, *ANTIVIRAL agents, *BONE marrow, *CYTOKINES, *INTERLEUKINS
Abstract

In patients with liver disease, thrombocytopenia is a clinical feature that may represent an obstacle to invasive diagnostic or therapeutic procedures, chemotherapy, and anti-viral treatment. Stimulation of the bone marrow is the most promising therapeutic intervention for thrombocytopenia in patients with chronic liver disease. The description of thrombopoietin and its (de)regulation in patients with chronic liver disease have disclosed new treatment opportunities. Indeed, pharmacologic treatment options for thrombocytopenia can be divided into treatments targeted at the thrombopoietin receptor (synthetic thrombopoietins and thrombopoietin-mimetic agents), and use of cytokines with general thrombopoietic potential. Unfortunately, use of synthetic thrombopoietin was hampered by the development of neutralizing antibodies, and thrombopoietin mimetic agents have not yet entered clinical studies. Interleukin-11 proved to be useful in increasing platelet count in patients with chronic liver disease, although its use is limited by side-effects. Erythropoietin has shown promising results in improving thrombocytopenia in cirrhotic patients. In patients with chronic liver disease, safe and well-tolerated treatments aimed at improving thrombocytopenia are still lacking. Larger studies are needed to evaluate and better characterize the thrombopoietic potential of erythropoietin. Human studies with thrombopoietin-mimetic agents are eagerly awaited in order to assess both effectiveness and safety of these drugs. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

20. Author's reply.

Author

Giannini, E. G., Botta, F., and Testa, R.

Subjects
*GASTROENTEROLOGY, *ENDOSCOPIC surgery, *ESOPHAGUS, *ENDOSCOPY, *QUANTITATIVE research, *GASTROENTERITIS, *DIAGNOSIS
Abstract

In this article, the authors, respond to comments made by some researchers, on their research related to gastroenterology. Authors says that as a general rule, a surrogate marker for a given variable, that is, presence/absence of oesophageal varices, that already has a definite diagnostic procedure, that is, endoscopy, should fulfil two major criteria. Firstly, it should be the product of a thorough statistical analysis and secondly, but no less importantly, it has to be biologically plausible. They further say that they have proposed a new evaluation tool and called for validation of proposed method, being conscious that only differences in opinion that arise from results obtained in well conducted studies contribute to scientific progress.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results